These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 32372094)

  • 1. Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study.
    Zabel M; Willems R; Lubinski A; Bauer A; Brugada J; Conen D; Flevari P; Hasenfuß G; Svetlosak M; Huikuri HV; Malik M; Pavlović N; Schmidt G; Sritharan R; Schlögl S; Szavits-Nossan J; Traykov V; Tuinenburg AE; Willich SN; Harden M; Friede T; Svendsen JH; Sticherling C; Merkely B;
    Eur Heart J; 2020 Sep; 41(36):3437-3447. PubMed ID: 32372094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study.
    Bauer A; Klemm M; Rizas KD; Hamm W; von Stülpnagel L; Dommasch M; Steger A; Lubinski A; Flevari P; Harden M; Friede T; Kääb S; Merkely B; Sticherling C; Willems R; Huikuri H; Malik M; Schmidt G; Zabel M;
    Lancet; 2019 Oct; 394(10206):1344-1351. PubMed ID: 31488371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of the EU-CERT-ICD prospective study: comparative effectiveness of prophylactic ICD implantation.
    Zabel M; Sticherling C; Willems R; Lubinski A; Bauer A; Bergau L; Braunschweig F; Brugada J; Brusich S; Conen D; Cygankiewicz I; Flevari P; Taborsky M; Hansen J; Hasenfuß G; Hatala R; Huikuri HV; Iovev S; Kääb S; Kaliska G; Kasprzak JD; Lüthje L; Malik M; Novotny T; Pavlović N; Schmidt G; Shalganov T; Sritharan R; Schlögl S; Szavits Nossan J; Traykov V; Tuinenburg AE; Velchev V; Vos MA; Willich SN; Friede T; Svendsen JH; Merkely B;
    ESC Heart Fail; 2019 Feb; 6(1):182-193. PubMed ID: 30299600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Present criteria for prophylactic ICD implantation: Insights from the EU-CERT-ICD (Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope) project.
    Zabel M; Schlögl S; Lubinski A; Svendsen JH; Bauer A; Arbelo E; Brusich S; Conen D; Cygankiewicz I; Dommasch M; Flevari P; Galuszka J; Hansen J; Hasenfuß G; Hatala R; Huikuri HV; Kenttä T; Kucejko T; Haarmann H; Harden M; Iovev S; Kääb S; Kaliska G; Katsimardos A; Kasprzak JD; Qavoq D; Lüthje L; Malik M; Novotný T; Pavlović N; Perge P; Röver C; Schmidt G; Shalganov T; Sritharan R; Svetlosak M; Sallo Z; Szavits-Nossan J; Traykov V; Vandenberk B; Velchev V; Vos MA; Willich SN; Friede T; Willems R; Merkely B; Sticherling C;
    J Electrocardiol; 2019; 57S():S34-S39. PubMed ID: 31526572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of Prognostic Value of T-Wave Alternans for Implantable Cardioverter-Defibrillator Benefit in Primary Prevention.
    Pelli A; Kenttä TV; Junttila MJ; Huber C; Schlögl S; Zabel M; Malik M; Willems R; Vos MA; Harden M; Friede T; Sticherling C; Huikuri HV;
    J Am Heart Assoc; 2024 Jun; 13(11):e032465. PubMed ID: 38804218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New York Heart Association functional class and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: Extended follow-up of the DANISH trial.
    Karacan MN; Doi SN; Yafasova A; Thune JJ; Nielsen JC; Haarbo J; Bruun NE; Gustafsson F; Eiskjær H; Hassager C; Svendsen JH; Høfsten DE; Pehrson S; Køber L; Butt JH
    Eur J Heart Fail; 2024 Jun; 26(6):1423-1431. PubMed ID: 38733253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-terminal pro-B-type natriuretic peptide is a specific predictor of appropriate device therapies in patients with primary prevention implantable cardioverter-defibrillators.
    Sroubek J; Matos J; Locke A; Kaplinskiy V; Levine YC; Shen C; Buxton AE
    Heart Rhythm; 2021 Jan; 18(1):71-78. PubMed ID: 32866691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic role of NYHA class in heart failure patients undergoing primary prevention ICD therapy.
    Briongos-Figuero S; Estévez A; Pérez ML; Martínez-Ferrer JB; García E; Viñolas X; Arenal Á; Alzueta J; Muñoz-Aguilera R
    ESC Heart Fail; 2020 Feb; 7(1):279-283. PubMed ID: 31823514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICD risk stratification studies - EU-CERT-ICD and the European perspective.
    Seegers J; Bergau L; Tichelbäcker T; Malik M; Zabel M
    J Electrocardiol; 2016; 49(6):831-836. PubMed ID: 27623399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implantable cardioverter-defibrillator therapy among patients with non-ischaemic vs. ischaemic cardiomyopathy for primary prevention of sudden cardiac death.
    Amara N; Boveda S; Defaye P; Klug D; Treguer F; Amet D; Perier MC; Gras D; Algalarrondo V; Bouzeman A; Piot O; Deharo JC; Fauchier L; Babuty D; Bordachar P; Sadoul N; Marijon E; Leclercq C;
    Europace; 2018 Jan; 20(1):65-72. PubMed ID: 28082419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival and arrhythmic risk among ischemic and non-ischemic heart failure patients with prophylactic implantable cardioverter defibrillator only therapy: A propensity score-matched analysis.
    Briongos-Figuero S; Estévez A; Luisa Pérez M; Martínez-Ferrer JB; García E; Viñolas X; Arenal Á; Alzueta J; Basterra N; Rodríguez A; Lozano I; Muñoz-Aguilera R
    Int J Cardiol; 2019 Jan; 274():163-169. PubMed ID: 30206014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Q waves are the strongest electrocardiographic variable associated with primary prophylactic implantable cardioverter-defibrillator benefit: a prospective multicentre study.
    Pelli A; Junttila MJ; Kenttä TV; Schlögl S; Zabel M; Malik M; Reichlin T; Willems R; Vos MA; Harden M; Friede T; Sticherling C; Huikuri HV;
    Europace; 2022 May; 24(5):774-783. PubMed ID: 34849744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of left ventricular ejection fraction and QRS duration on the survival benefit of implantable cardioverter-defibrillators: meta-analysis of primary prevention trials.
    Katritsis DG; Siontis KC; Bigger JT; Kadish AH; Steinman R; Zareba W; Siontis GC; Bardy GH; Ioannidis JP
    Heart Rhythm; 2013 Feb; 10(2):200-6. PubMed ID: 23107652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation.
    Algalarrondo V; Perault R; Bories MC; Narayanan K; Garcia R; Combes N; Perier MC; Defaye P; Sadoul N; Gras D; Klug D; Bordachar P; Fauchier L; Deharo JC; Leclercq C; Boveda S; Marijon E; Babuty D;
    Arch Cardiovasc Dis; 2018 Dec; 111(12):758-765. PubMed ID: 30078651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kidney dysfunction and deterioration of ejection fraction pose independent risk factors for mortality in implantable cardioverter-defibrillator recipients for primary prevention.
    Kreuz J; Horlbeck F; Schrickel J; Linhart M; Fimmers R; Mellert F; Nickenig G; Schwab JO
    Clin Cardiol; 2012 Sep; 35(9):575-9. PubMed ID: 22707222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Benefit of Prophylactic Implantable Cardioverter Defibrillator Implantation in Asymptomatic Heart Failure Patients With a Reduced Ejection Fraction.
    van der Lingen ACJ; Timmer SAJ; Allaart LJH; Rijnierse MT; van de Ven PM; van Rossum AC; Kemme MJB; van Halm VP; Allaart CP
    Am J Cardiol; 2019 Aug; 124(4):560-566. PubMed ID: 31270031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Hypertrophic Cardiomyopathy.
    Goldstein SA; Kennedy KF; Friedman DJ; Al-Khatib SM; Wang A
    J Am Heart Assoc; 2023 Aug; 12(16):e029293. PubMed ID: 37586066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients.
    Jukema JW; Timal RJ; Rotmans JI; Hensen LCR; Buiten MS; de Bie MK; Putter H; Zwinderman AH; van Erven L; Krol-van Straaten MJ; Hommes N; Gabreëls B; van Dorp W; van Dam B; Herzog CA; Schalij MJ; Rabelink TJ;
    Circulation; 2019 Jun; 139(23):2628-2638. PubMed ID: 30882234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.